VivoSeq
Other

Function

1

Pipeline Programs

55

Active Trials

64

Companies Involved

Function is an early-stage landscape with 1 program across 64 companies. The most active players are Eli Lilly, Pfizer, GSK.

Pipeline Metrics

Competitive Density

51/100

Pipeline Velocity

48/100

Mech. Concentration

N/A

Completion Rate

87/100

Attrition Rate

10/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 3
No programs
Approved
No programs

Trial Status

511

clinical trials

Completed334 · 65%
Unknown status69 · 14%
Recruiting37 · 7%
Terminated34 · 7%
Withdrawn18 · 4%
Not yet recruiting12 · 2%
Other7 · 1%

Trial Activity

511 trials

NAL ER IPF Respiratory Function and Safety Study
Recruiting·TTrevi Therapeutics·Phase 1·NCT07036029·10 enrolled
The Effect of Naldemedine on Opioid-induced Bowel Dysfunction
Recruiting··Phase 2·NCT06334198·20 enrolled
Page 1 of 35

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)